MLYS · Mineralys Therapeutics, Inc. · Insider Trading

Consists of restricted stock units (RSUs) granted for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of three years, with 1/3rd of the RSUs vesting on each one-year anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

Consists of restricted stock units (RSUs) granted for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of three years, with 1/3rd of the RSUs vesting on each one-year anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

The shares underlying the stock option vest in monthly installments over a period of three years, with 1/36th of the underlying shares vesting on each monthly anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

The shares underlying the stock option vest in monthly installments over a period of three years, with 1/36th of the underlying shares vesting on each monthly anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.8201. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3).

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

The stock option vests in 36 monthly installments beginning on October 13, 2023.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.965 to $27.750. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.58. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.5600 to $26.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.6450 to $26.8200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

The stock option vests in 36 monthly installments beginning on October 13, 2023.